156P The impact of the COVID-19 pandemic on the treatment patterns of patients with stage III unresectable non-small cell lung cancer

The aim of this study was to understand the impact of the COVID-19 pandemic on the treatment patterns for patients with stage III unresectable non-small cell lung cancer (uNSCLC). This was a retrospective chart review study of stage III uNSCLC patients diagnosed between 1 October 2017 and 31 May 2021 in France, Germany, Italy, Spain, Canada, and the USA. Of 351 enrolled patients (median age 70 years [range 44-91]; 63.5% male), 88 and 263 were treated prior to (Cohort 1) and during (Cohort 2) the pandemic, respectively. The majority in Cohort 1 (89.8%) and Cohort 2 (82.5%) received platinum-based chemoradiotherapy (CRT). Among patients receiving CRT, the proportion who received sequential CRT (sCRT) was higher in Cohort 2 compared to Cohort 1 (20.3% vs 12.7%). Median treatment durations of completed concurrent CRT and sCRT were 64.0 and 145.5 days, respectively, in all patients and similar between cohorts. A higher proportion received consolidation durvalumab in Cohort 2 compared to Cohort 1 (67.3% vs 40.5%). Compared to Cohort 1, Cohort 2 had a lower median time to durvalumab initiation (41.0 vs 51.5 days since CRT end) and a longer median duration of durvalumab treatment (336.0 vs 147.5 days). Among all patients, a higher proportion of Cohort 2 experienced dose/schedule modifications compared to Cohort 1 (28.1% vs 14.8%). The proportion of patients experiencing any adverse events (AEs) of interest was similar between Cohort 1 (67.0%) and Cohort 2 (67.3%). Of AEs collected, lower proportions were reported in Cohort 2 vs Cohort 1 for pneumonitis (7.8% vs 14.9%) and interstitial lung disease (0% vs 3.2%). In this study, stage III uNSCLC patients continued to receive the SOC during the pandemic (Cohort 2), with a higher proportion receiving durvalumab, a shorter time to durvalumab initiation, and a longer durvalumab treatment duration compared to prior to the pandemic (Cohort 1). Higher proportions of patients in Cohort 2 compared to Cohort 1 received sCRT and had dose/schedule modifications to potentially help mitigate toxicities and alleviate healthcare system burden. SOC was maintained during the pandemic, indicating a strong attention to patient care and increased awareness of the PACIFIC regimen.